PharmaNova Inc. is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using our proprietary nanoparticle technology platform and other complementary formulation and drug delivery technologies.
Piercell is a nanotechnology venture that is developing a biomolecular delivery device that pierces into primary and other hard-to-transfect cells. Piercell's vision is to pave the path to cell therapy by enabling ex vivo DNA and RNA drug delivery into clinically relevant cells of patients.
Pioneer Surgical Technology is a leading innovator in the design and manufacture of spinal and orthopaedic implants and instruments. The company's proprietary nanocrystalline hydroxyapatite technology - NanOss™ Bone Void Filler - is the first ever nanotechnology medical device to receive clearance by the US Food and Drug Administration (FDA). NanOss™ is an innovative structural biomaterial that is highly osteoconductive and remodels over time into human bone with applications in the sports medicine, trauma, spine and general orthopaedics markets.
The company develops, produces and markets nanotechnologies for the life sciences. They produce a variety of nano-structured surfaces for use in research and are also developing a range of products that derive from a proprietary platform technology using liquid crystals for the rapid detection of molecular interactions.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to deliver easily and cost-effectively customized wound care on-demand for each patient's unique wound.
The company is developing intelligent medicine products internally and in partnership with device, pharmaceutical and biotechnology companies. These products address therapeutic areas where disease management complexity, patient monitoring requirements, therapeutic efficacy, and poor patient adherence create large clinical and commercial opportunities.
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.